Recruiting

Patient-Centric Study to Assess the Impact of Genomic Profiling on the Treatment of Patients With Metastatic Breast Cancer in Spain

ClinicalTrials.gov IDNCT06991946

PhaseNot Applicable

Enrollment300

SponsorSOLTI Breast Cancer Research Group

Age18 Years

SexALL

I'm interested View official listing

Conditions studied

Metastatic Breast Cancer

About this study

HOPE Focus is an observational study that aims at promoting research against metastatic breast cancer by means of collective research led by patients (patient-centric trial). Patients with metastatic breast cancer living in Spain will voluntarily register and fulfil their journey in the study through the study's digital tool. Mainly they are prompted to answer questionnaires about their disease and expectations, and to provide a blood sample and an archival tumor biopsy. In HOPE Focus these samples will be genomically analyzed and every patient case will be presented in a multidisciplinary molecular advisory board (MAB). The MAB will issue a plain report explaining the significance of the results and will enumerate future therapeutic options that match patient history and his genomic profile, when feasible. Finally, patients will have to answer short follow-up questionnaires twice a year for 3 years. The study data will allow us to advance implementing precision medicine to improve the management of current and specially future metastatic breast cancer patients.

Interventions

Genetic: Liquid Biopsy — Patients with metastatic breast cancer in disease progression will undergo a liquid biopsy
Genetic: Archival Tumor DNA — Patients will be prompted to request an archival tumor sample from metastatic origin (preferably) and to send it to the central laboratory for analysis

Primary outcomes

To evaluate the feasibility of incorporating a molecular diagnosis in the management of patients with metastatic breast cancer following a patient-centric strategy. (Ongoing basis during 5 years of study duration)

Eligibility information

Inclusion Criteria: 1. Female or male patients residing in Spain. 2. Age ≥ 18 years. 3. Signed informed consent prior to any study-related procedures, except for registration. 4. Self-reported Eastern Cooperative Oncology Group (ECOG) performance status of 0-1. 5. Patients with metastatic breast cancer in at least one of these situations: 1. Patients recently diagnosed with ER+/HER2- metastatic breast cancer as a recurrence during adjuvant treatment and prior to initiating any treatment in the metastatic setting. 2. Patients with metastatic breast cancer of any subtype that have progressed after at least one line of treatment in the metastatic setting. Exclusion Criteria: 1. Presence of a condition or abnormality that, in the opinion of the investigators, would compromise the safety of the patient or the quality of the data. 2. Inability or refusal to commit with the procedures of the study at the moment of inclusion. 3. More than 3 prior systemic chemotherapy or antibody-drug conjugate (ADC) regimens for metastatic disease. Note: treatments for bone metastases (eg, bisphosphonates, denosumab, etc.), targeted therapies (eg, PARP inhibitors, CDK 4/6 inhibitors, immunotherapy etc.) and hormonal therapy are not considered as prior systemic chemotherapy treatments for advanced disease.

Study locations

SOLTI Cancer Research Group, Barcelona, Barcelona 08008 Spain

Before you participate: Varda Clinical is an independent discovery tool, not the study sponsor or a medical provider. Eligibility can only be determined by the official study team. Discuss potential risks and benefits with a qualified healthcare professional.

Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-09-28.